{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:27:52Z","timestamp":1778869672950,"version":"3.51.4"},"reference-count":98,"publisher":"Wiley","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["FEBS Letters"],"abstract":"<jats:p>Inherited metabolic disorders (IMDs) are a growing group of genetic diseases caused by defects in enzymes that mediate cellular metabolism, often resulting in the accumulation of toxic substrates. The liver is a highly metabolically active organ that hosts several thousands of chemical reactions. As such, it is an organ frequently affected in IMDs. In this article, we review current approaches for liver\u2010directed gene\u2010based therapy aimed at metabolite detoxification in a variety of IMDs. Moreover, we discuss current unresolved challenges in gene\u2010based therapies for IMDs.<\/jats:p>","DOI":"10.1002\/1873-3468.14957","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:59:03Z","timestamp":1718625543000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Liver gene transfer for metabolite detoxification in inherited metabolic diseases"],"prefix":"10.1002","author":[{"given":"Alfonso M.","family":"D'Alessio","sequence":"first","affiliation":[{"name":"Telethon Institute of Genetics and Medicine (TIGEM)  Pozzuoli Italy"},{"name":"Scuola Superiore Meridionale (SSM, School of Advanced Studies), Genomics and Experimental Medicine Program University of Naples Federico II  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iolanda","family":"Boffa","sequence":"additional","affiliation":[{"name":"Telethon Institute of Genetics and Medicine (TIGEM)  Pozzuoli Italy"},{"name":"Azienda Ospedaliera Universitaria Federico II  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Telethon Institute of Genetics and Medicine (TIGEM)  Pozzuoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro R.","family":"Soria","sequence":"additional","affiliation":[{"name":"Telethon Institute of Genetics and Medicine (TIGEM)  Pozzuoli Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-8819","authenticated-orcid":false,"given":"Nicola","family":"Brunetti\u2010Pierri","sequence":"additional","affiliation":[{"name":"Telethon Institute of Genetics and Medicine (TIGEM)  Pozzuoli Italy"},{"name":"Scuola Superiore Meridionale (SSM, School of Advanced Studies), Genomics and Experimental Medicine Program University of Naples Federico II  Naples Italy"},{"name":"Department of Translational Medicine Federico II University of Naples  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"R1147","DOI":"10.1016\/j.cub.2017.09.019","article-title":"The liver","volume":"27","author":"Trefts E","year":"2017","journal-title":"Curr Biol"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev-pathmechdis-031521-024831","article-title":"Spatiotemporal metabolic liver zonation and consequences on pathophysiology","volume":"18","author":"Martini T","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41575-019-0134-x","article-title":"Spatial heterogeneity in the mammalian liver","volume":"16","author":"Ben\u2010Moshe S","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jimd.12348","article-title":"An international classification of inherited metabolic disorders (ICIMD)","volume":"44","author":"Ferreira CR","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.105.1.e10","article-title":"Incidence of inborn errors of metabolism in British Columbia, 1969\u20131996","volume":"105","author":"Applegarth DA","year":"2000","journal-title":"Pediatrics"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/petr.12741","article-title":"Liver transplantation for pediatric inherited metabolic disorders: considerations for indications, complications, and perioperative management","volume":"20","author":"Oishi K","year":"2016","journal-title":"Pediatr Transplant"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200052","article-title":"Liver\u2010directed adeno\u2010associated virus\u2010mediated gene therapy for mucopolysaccharidosis type VI","volume":"1","author":"Brunetti\u2010Pierri N","year":"2022","journal-title":"NEJM Evid"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno\u2010associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu Z","year":"2006","journal-title":"Mol Ther"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno\u2010associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang D","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"10462","DOI":"10.1128\/JVI.00935-12","article-title":"Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno\u2010associated virus type 2 particles are facilitated by microtubule network","volume":"86","author":"Xiao PJ","year":"2012","journal-title":"J Virol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"15047","DOI":"10.1038\/mtm.2015.47","article-title":"Super\u2010resolution imaging of nuclear import of adeno\u2010associated virus in live cells","volume":"2","author":"Kelich JM","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/jvi.70.5.3227-3234.1996","article-title":"Second\u2010strand synthesis is a rate\u2010limiting step for efficient transduction by recombinant adeno\u2010associated virus vectors","volume":"70","author":"Ferrari FK","year":"1996","journal-title":"J Virol"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno\u2010associated virus","volume":"7","author":"Dong JY","year":"1996","journal-title":"Hum Gene Ther"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno\u2010associated viruses","volume":"199","author":"Calcedo R","year":"2009","journal-title":"J Infect Dis"},{"key":"e_1_2_10_16_1","first-page":"379","article-title":"Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions","volume":"15","author":"Masat E","year":"2013","journal-title":"Discov Med"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jhep.2023.10.029","article-title":"Adeno\u2010associated viruses for gene therapy \u2010 clinical implications and liver\u2010related complications, a guide for hepatologists","volume":"80","author":"Mucke MM","year":"2024","journal-title":"J Hepatol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno\u2010associated virus vector genomes are primarily responsible for stable liver transduction in vivo","volume":"75","author":"Nakai H","year":"2001","journal-title":"J Virol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2005.07.015","article-title":"Gene therapy for inborn errors of liver metabolism","volume":"86","author":"Brunetti\u2010Pierri N","year":"2005","journal-title":"Mol Genet Metab"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2021.100300","article-title":"Novel vectors and approaches for gene therapy in liver diseases","volume":"3","author":"Maestro S","year":"2021","journal-title":"JHEP Rep"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis\u2010shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani M","year":"2019","journal-title":"Sci Transl Med"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An D","year":"2017","journal-title":"Cell Rep"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1038\/s41467-021-23318-2","article-title":"mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease","volume":"12","author":"Cao J","year":"2021","journal-title":"Nat Commun"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","article-title":"Interim analyses of a first\u2010in\u2010human phase 1\/2 mRNA trial for propionic acidaemia","volume":"628","author":"Koeberl D","year":"2024","journal-title":"Nature"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","article-title":"Non\u2010viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets","volume":"27","author":"Conway A","year":"2019","journal-title":"Mol Ther"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/hep.30959","article-title":"Crigler\u2010Najjar syndrome type 1: pathophysiology, natural history, and therapeutic frontier","volume":"71","author":"Strauss KA","year":"2020","journal-title":"Hepatology"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa2214084","article-title":"Gene therapy in patients with the Crigler\u2010Najjar syndrome","volume":"389","author":"D'Antiga L","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128863","article-title":"Coupling AAV\u2010mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases","volume":"5","author":"De Caneva A","year":"2019","journal-title":"JCI Insight"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101161","article-title":"CRISPR\u2010Cas9\u2010mediated somatic correction of a one\u2010base deletion in the Ugt1a gene ameliorates hyperbilirubinemia in Crigler\u2010Najjar syndrome mice","volume":"31","author":"Bortolussi G","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV\u2010CRISPR gene editing is negated by pre\u2010existing immunity to Cas9","volume":"28","author":"Li A","year":"2020","journal-title":"Mol Ther"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2023.02.007","article-title":"Lipid nanoparticle\u2010encapsulated mRNA therapy corrects serum total bilirubin level in Crigler\u2010Najjar syndrome mouse model","volume":"29","author":"Greig JA","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","article-title":"Adherence to clinic recommendations among patients with phenylketonuria in the United States","volume":"120","author":"Jurecki ER","year":"2017","journal-title":"Mol Genet Metab"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199307293290517","article-title":"Correction of phenylketonuria after liver transplantation in a child with cirrhosis","volume":"329","author":"Vajro P","year":"1993","journal-title":"N Engl J Med"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.gt.3302678","article-title":"Complete correction of hyperphenylalaninemia following liver\u2010directed, recombinant AAV2\/8 vector\u2010mediated gene therapy in murine phenylketonuria","volume":"13","author":"Harding CO","year":"2006","journal-title":"Gene Ther"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","article-title":"AAV\u2010mediated CRISPR\/Cas9 gene editing in murine phenylketonuria","volume":"17","author":"Richards DY","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger L","year":"2018","journal-title":"Nat Med"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41551-020-00671-z","article-title":"In vivo cytidine base editing of hepatocytes without detectable off\u2010target mutations in RNA and DNA","volume":"5","author":"Villiger L","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.ajhg.2023.10.005","article-title":"Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need","volume":"110","author":"Brooks DL","year":"2023","journal-title":"Am J Hum Genet"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pcl.2017.11.004","article-title":"Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders","volume":"65","author":"Summar ML","year":"2018","journal-title":"Pediatr Clin N Am"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/jimd.12100","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision","volume":"42","author":"Haberle J","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.omtm.2021.09.005","article-title":"Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys","volume":"23","author":"Baruteau J","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.omtm.2020.11.005","article-title":"Long\u2010term correction of ornithine transcarbamylase deficiency in Spf\u2010ash mice with a translationally optimized AAV vector","volume":"20","author":"De Sabbata G","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ymgme.2018.08.013","article-title":"Adeno\u2010associated viral gene therapy corrects a mouse model of argininosuccinic aciduria","volume":"125","author":"Ashley SN","year":"2018","journal-title":"Mol Genet Metab"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/mt.2012.129","article-title":"Long\u2010term survival of the juvenile lethal arginase\u2010deficient mouse with AAV gene therapy","volume":"20","author":"Lee EK","year":"2012","journal-title":"Mol Ther"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hum.2018.098","article-title":"Age\u2010related seroprevalence of antibodies against AAV\u2010LK03 in a UK population cohort","volume":"30","author":"Perocheau DP","year":"2019","journal-title":"Hum Gene Ther"},{"key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/mt.2008.72","article-title":"Gene delivery to the juvenile mouse liver using AAV2\/8 vectors","volume":"16","author":"Cunningham SC","year":"2008","journal-title":"Mol Ther"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2011.151","article-title":"AAV8\u2010mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta)","volume":"19","author":"Wang L","year":"2011","journal-title":"Mol Ther"},{"key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/hum.2011.183","article-title":"Hepatic gene transfer in neonatal mice by adeno\u2010associated virus serotype 8 vector","volume":"23","author":"Wang L","year":"2012","journal-title":"Hum Gene Ther"},{"key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2017.12.024","article-title":"Targeted mRNA therapy for ornithine Transcarbamylase deficiency","volume":"26","author":"Prieve MG","year":"2018","journal-title":"Mol Ther"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtn.2023.06.023","article-title":"Lipid nanoparticle\u2010targeted mRNA formulation as a treatment for ornithine\u2010transcarbamylase deficiency model mice","volume":"33","author":"Yamazaki K","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh1334","article-title":"mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria","volume":"16","author":"Gurung S","year":"2024","journal-title":"Sci Transl Med"},{"key":"e_1_2_10_52_1","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle\u2010targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong B","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_2_10_53_1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.omtn.2022.04.012","article-title":"Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency","volume":"28","author":"Khoja S","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"e_1_2_10_54_1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI67217","article-title":"Biochemical correlates of neuropsychiatric illness in maple syrup urine disease","volume":"123","author":"Muelly ER","year":"2013","journal-title":"J Clin Invest"},{"key":"e_1_2_10_55_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpeds.2011.06.033","article-title":"Liver transplantation for classical maple syrup urine disease: long\u2010term follow\u2010up in 37 patients and comparative united network for organ sharing experience","volume":"160","author":"Mazariegos GV","year":"2012","journal-title":"J Pediatr"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jimd.12604","article-title":"Successful treatment of severe MSUD in Bckdhb(\u2212\/\u2212) mice with neonatal AAV gene therapy","volume":"47","author":"Pontoizeau C","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"e_1_2_10_57_1","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/s41467-022-30880-w","article-title":"Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice","volume":"13","author":"Pontoizeau C","year":"2022","journal-title":"Nat Commun"},{"key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymgme.2021.08.003","article-title":"Muscle\u2010directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model","volume":"134","author":"Greig JA","year":"2021","journal-title":"Mol Genet Metab"},{"key":"e_1_2_10_59_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ymgme.2013.10.018","article-title":"Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring","volume":"111","author":"Stockler\u2010Ipsiroglu S","year":"2014","journal-title":"Mol Genet Metab"},{"key":"e_1_2_10_60_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/mgme.2001.3257","article-title":"Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation","volume":"74","author":"Schulze A","year":"2001","journal-title":"Mol Genet Metab"},{"key":"e_1_2_10_61_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.omtm.2022.03.015","article-title":"Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities","volume":"25","author":"Khoja S","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_62_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajmg.c.30088","article-title":"Glutaric acidemia type 1","volume":"142","author":"Hedlund GL","year":"2006","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"e_1_2_10_63_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf4086","article-title":"Rescue of glutaric aciduria type I in mice by liver\u2010directed therapies","volume":"15","author":"Barzi M.","year":"2023","journal-title":"Sci Transl Med"},{"key":"e_1_2_10_64_1","first-page":"3302","article-title":"Ornithine delta\u2010aminotransferase mutations in gyrate atrophy","volume":"267","author":"Brody LC","year":"1992","journal-title":"Allelic Heterogeneity and Functional Consequences, J Biol Chem"},{"key":"e_1_2_10_65_1","first-page":"616","article-title":"Pyridoxine\u2010responsive gyrate atrophy of the choroid and retina: clinical and biochemical correlates of the mutation A226V","volume":"56","author":"Michaud J","year":"1995","journal-title":"Am J Hum Genet"},{"key":"e_1_2_10_66_1","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217033","article-title":"Liver\u2010directed gene therapy for ornithine aminotransferase deficiency","volume":"15","author":"Boffa I","year":"2023","journal-title":"EMBO Mol Med"},{"key":"e_1_2_10_67_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s44321-023-00001-1","article-title":"Vision on gyrate atrophy: why treat the eye?","volume":"16","author":"Bergen A. A.","year":"2024","journal-title":"EMBO Mol Med"},{"key":"e_1_2_10_68_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44321-023-00002-0","article-title":"Vision on gyrate atrophy: why treat the liver?","volume":"16","author":"Boffa I","year":"2024","journal-title":"EMBO Mol Med"},{"key":"e_1_2_10_69_1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00467-014-3030-1","article-title":"Primary hyperoxalurias: diagnosis and treatment","volume":"30","author":"Ben\u2010Shalom E","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_10_70_1","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype\u2010genotype correlations and estimated carrier frequencies of primary hyperoxaluria","volume":"26","author":"Hopp K","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_10_71_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/gt.2015.107","article-title":"Helper\u2010dependent adenoviral vectors for liver\u2010directed gene therapy of primary hyperoxaluria type 1","volume":"23","author":"Castello R","year":"2016","journal-title":"Gene Ther"},{"key":"e_1_2_10_72_1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1681\/ASN.2016030338","article-title":"An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria","volume":"28","author":"Liebow A","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_10_73_1","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","article-title":"Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria","volume":"26","author":"Lai C","year":"2018","journal-title":"Mol Ther"},{"key":"e_1_2_10_74_1","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1038\/s41467-018-07827-1","article-title":"CRISPR\/Cas9\u2010mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I","volume":"9","author":"Zabaleta N","year":"2018","journal-title":"Nat Commun"},{"key":"e_1_2_10_75_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s44321-023-00008-8","article-title":"Efficient and safe therapeutic use of paired Cas9\u2010nickases for primary hyperoxaluria type 1","volume":"16","author":"Torella L","year":"2024","journal-title":"EMBO Mol Med"},{"key":"e_1_2_10_76_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41587-020-00756-9","article-title":"Safety questions for AAV gene therapy","volume":"39","author":"Venditti CP","year":"2021","journal-title":"Nat Biotechnol"},{"key":"e_1_2_10_77_1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a Long journey to successful gene transfer","volume":"28","author":"Verdera HC","year":"2020","journal-title":"Mol Ther"},{"key":"e_1_2_10_78_1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG\u2010cleaving endopeptidase enables in vivo gene therapy in the presence of anti\u2010AAV neutralizing antibodies","volume":"26","author":"Leborgne C","year":"2020","journal-title":"Nat Med"},{"key":"e_1_2_10_79_1","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen\u2010selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re\u2010administration","volume":"9","author":"Meliani A","year":"2018","journal-title":"Nat Commun"},{"key":"e_1_2_10_80_1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS\u2010101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand D","year":"2021","journal-title":"J Hepatol"},{"key":"e_1_2_10_81_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following Onasemnogene Abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand DH","year":"2021","journal-title":"J Pediatr"},{"key":"e_1_2_10_82_1","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High\u2010dose systemic adeno\u2010associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux J","year":"2024","journal-title":"Mol Ther"},{"key":"e_1_2_10_83_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high\u2010dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy","volume":"389","author":"Lek A","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_10_84_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X\u2010linked myotubular myopathy (ASPIRO): a multinational, open\u2010label, dose\u2010escalation trial","volume":"22","author":"Shieh PB","year":"2023","journal-title":"Lancet Neurol"},{"key":"e_1_2_10_85_1","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3505","article-title":"Successful liver transduction by re\u2010administration of different adeno\u2010associated virus vector serotypes in mice","volume":"25","author":"Baatartsogt N","year":"2023","journal-title":"J Gene Med"},{"key":"e_1_2_10_86_1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ymthe.2020.05.007","article-title":"Immunity to Cas9 as an obstacle to persistent genome editing","volume":"28","author":"Gough V","year":"2020","journal-title":"Mol Ther"},{"key":"e_1_2_10_87_1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/nm.4377","article-title":"Implications of human genetic variation in CRISPR\u2010based therapeutic genome editing","volume":"23","author":"Scott DA","year":"2017","journal-title":"Nat Med"},{"key":"e_1_2_10_88_1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR\u2013Cas9 genome editing induces a p53\u2010mediated DNA damage response","volume":"24","author":"Haapaniemi E","year":"2018","journal-title":"Nat Med"},{"key":"e_1_2_10_89_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","article-title":"p53 inhibits CRISPR\u2013Cas9 engineering in human pluripotent stem cells","volume":"24","author":"Ihry RJ","year":"2018","journal-title":"Nat Med"},{"key":"e_1_2_10_90_1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41588-020-0623-4","article-title":"Cas9 activates the p53 pathway and selects for p53\u2010inactivating mutations","volume":"52","author":"Enache OM","year":"2020","journal-title":"Nat Genet"},{"key":"e_1_2_10_91_1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno\u2010associated virus gene therapy","volume":"125","author":"Chandler RJ","year":"2015","journal-title":"J Clin Invest"},{"key":"e_1_2_10_92_1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2\u2010related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault JC","year":"2015","journal-title":"Nat Genet"},{"key":"e_1_2_10_93_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno\u2010associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella T","year":"2020","journal-title":"Gut"},{"key":"e_1_2_10_94_1","first-page":"1081","article-title":"Prevalent and disseminated recombinant and wild\u2010type adeno\u2010associated virus integration in macaques and humans","volume":"34","author":"Martins KM","year":"2023","journal-title":"Hum Gene Ther"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587\u2010023\u201001974\u20107"},{"key":"e_1_2_10_96_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long\u2010term study of AAV gene therapy in dogs with hemophilia a identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen GN","year":"2021","journal-title":"Nat Biotechnol"},{"key":"e_1_2_10_97_1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.omtm.2018.01.002","article-title":"Pharmacology of recombinant adeno\u2010associated virus production","volume":"8","author":"Penaud\u2010Budloo M","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_2_10_98_1","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41591-022-01934-9","article-title":"Ensuring a future for gene therapy for rare diseases","volume":"28","author":"Aiuti A","year":"2022","journal-title":"Nat Med"},{"key":"e_1_2_10_99_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature21065","article-title":"Single\u2010cell spatial reconstruction reveals global division of labour in the mammalian liver","volume":"542","author":"Halpern KB","year":"2017","journal-title":"Nature"}],"container-title":["FEBS Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1873-3468.14957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:59:57Z","timestamp":1718625597000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1873-3468.14957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":98,"alternative-id":["10.1002\/1873-3468.14957"],"URL":"https:\/\/doi.org\/10.1002\/1873-3468.14957","archive":["Portico"],"relation":{},"ISSN":["0014-5793","1873-3468"],"issn-type":[{"value":"0014-5793","type":"print"},{"value":"1873-3468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"2024-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1873-3468.14957"}}